Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuhiro Nako

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Endocrinology, Diabetes & Metabolism|March 1, 2019
Effects of sodium-glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretionSusumu Ogawa, Kazuhiro Nako, Sadayoshi Ito
BMJ Open Diabetes Research & Care|July 10, 2015
Lower urinary pH is useful for predicting renovascular disorder onset in patients with diabetesSusumu Ogawa, Kazuhiro Nako, Masashi Okamura, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 22, 2008
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathySusumu Ogawa, Takefumi Mori, Kazuhiro Nako, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 1, 2008
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetesSusumu Ogawa, Takefumi Mori, Kazuhiro Nako, et al.
Clinical and Experimental Pharmacology & Physiology|May 17, 2006
Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitorSusumu Ogawa, Kazuhisa Takeuchi, Takefumi Mori, et al.
Journal of Diabetes Investigation|July 30, 2015
Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapySusumu Ogawa, Kazuhiro Nako, Masashi Okamura, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 2, 2007
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathySusumu Ogawa, Kazuhisa Takeuchi, Takefumi Mori, et al.
Clinical and Experimental Nephrology|August 21, 2014
The strong relation between post-hemodialysis blood methylglyoxal levels and post-hemodialysis blood glucose concentration riseMiho Senda, Susumu Ogawa, Kazuhiro Nako, et al.
Hypertension (Dallas, Tex. : 1979)|March 1, 2006
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathySusumu Ogawa, Takefumi Mori, Kazuhiro Nako, et al.
Endocrine Journal|July 13, 2012
The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndromeMiho Senda, Susumu Ogawa, Kazuhiro Nako, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Endocrinology, Diabetes & Metabolism|March 1, 2019
Effects of sodium-glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretionSusumu Ogawa, Kazuhiro Nako, Sadayoshi Ito
BMJ Open Diabetes Research & Care|July 10, 2015
Lower urinary pH is useful for predicting renovascular disorder onset in patients with diabetesSusumu Ogawa, Kazuhiro Nako, Masashi Okamura, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 22, 2008
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathySusumu Ogawa, Takefumi Mori, Kazuhiro Nako, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 1, 2008
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetesSusumu Ogawa, Takefumi Mori, Kazuhiro Nako, et al.
Clinical and Experimental Pharmacology & Physiology|May 17, 2006
Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitorSusumu Ogawa, Kazuhisa Takeuchi, Takefumi Mori, et al.
Journal of Diabetes Investigation|July 30, 2015
Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapySusumu Ogawa, Kazuhiro Nako, Masashi Okamura, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 2, 2007
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathySusumu Ogawa, Kazuhisa Takeuchi, Takefumi Mori, et al.
Clinical and Experimental Nephrology|August 21, 2014
The strong relation between post-hemodialysis blood methylglyoxal levels and post-hemodialysis blood glucose concentration riseMiho Senda, Susumu Ogawa, Kazuhiro Nako, et al.
Hypertension (Dallas, Tex. : 1979)|March 1, 2006
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathySusumu Ogawa, Takefumi Mori, Kazuhiro Nako, et al.
Endocrine Journal|July 13, 2012
The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndromeMiho Senda, Susumu Ogawa, Kazuhiro Nako, et al.
Pageof 3